Catalogo dei prodotti della ricerca

BARATTA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.246
EU - Europa 1.211
AS - Asia 674
SA - Sud America 19
AF - Africa 17
OC - Oceania 7
Totale 5.174
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.213
IT - Italia 697
SG - Singapore 277
CN - Cina 149
IN - India 148
SE - Svezia 100
BG - Bulgaria 72
DE - Germania 72
FI - Finlandia 50
IE - Irlanda 42
ID - Indonesia 40
GB - Regno Unito 33
CA - Canada 29
FR - Francia 28
JO - Giordania 24
NL - Olanda 19
RO - Romania 19
RU - Federazione Russa 16
UA - Ucraina 15
TR - Turchia 14
AR - Argentina 13
TG - Togo 12
AT - Austria 11
AU - Australia 7
PL - Polonia 7
BE - Belgio 6
CH - Svizzera 6
GR - Grecia 6
HK - Hong Kong 6
TN - Tunisia 5
PH - Filippine 4
ES - Italia 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
BR - Brasile 2
JM - Giamaica 2
MX - Messico 2
MY - Malesia 2
RS - Serbia 2
SY - Repubblica araba siriana 2
BD - Bangladesh 1
BO - Bolivia 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
EC - Ecuador 1
HR - Croazia 1
IR - Iran 1
KR - Corea 1
LT - Lituania 1
MK - Macedonia 1
MM - Myanmar 1
SA - Arabia Saudita 1
UZ - Uzbekistan 1
Totale 5.174
Salva come PNG Salva come JPEG
Città #
Fairfield 538
Rome 279
Woodbridge 235
Ashburn 233
Seattle 212
Houston 199
Singapore 189
Chandler 186
Cambridge 183
Wilmington 168
Ann Arbor 129
Dearborn 102
Princeton 88
San Paolo di Civitate 80
Santa Clara 77
Sofia 72
Beijing 61
Millbury 57
Fremont 56
Lawrence 56
Dublin 42
Plano 42
Jakarta 40
New York 37
San Diego 28
Milan 26
Andover 23
Bremen 21
Amman 19
Helsinki 19
Boston 18
Norwalk 17
Mannheim 13
Phoenix 13
Lomé 12
Moscow 12
Ottawa 12
Toronto 12
Samsun 10
Boardman 9
Glendale 9
Los Angeles 9
Amsterdam 8
Dallas 8
Rochester 8
Vienna 8
Falls Church 7
Federal 7
Hyderabad 7
London 7
Redwood City 7
Bologna 6
Geneva 6
Hong Kong 6
Nanjing 6
San Severo 6
Southend 6
Bari 5
Buenos Aires 5
Des Moines 5
Fuzhou 5
Kunming 5
Megrine 5
Monterotondo 5
Naples 5
Sacramento 5
Stockholm 5
Velletri 5
Zarqa 5
Arezzo 4
Asti 4
Bermondsey 4
Brussels 4
Cagliari 4
Cascina 4
Frankfurt am Main 4
Genoa 4
Hefei 4
Marseille 4
Menlo Park 4
Mesa 4
Paris 4
Pescara 4
Sabaudia 4
Salerno 4
Surat 4
Turin 4
Bovezzo 3
Bromley 3
Catania 3
Chengdu 3
Falkenstein 3
Florence 3
Grafing 3
Groningen 3
Izmir 3
Jacksonville 3
Latina 3
L’Aquila 3
Meda 3
Totale 3.917
Salva come PNG Salva come JPEG
Nome #
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 169
Carotid plaque detection improves the predictve value of CHA2DS2-VASc score in patients with non-valvular atrial fibrilation. the ARAPACIS study 162
Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis 145
Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study 118
Adherence to mediterranean diet and non-alcoholic fatty liver disease. effect on insulin resistance 111
Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy 106
Off-label use of ceftaroline fosamil: a systematic review 103
Under-prescription of statins in patients with non-alcoholic fatty liver disease 101
PNPLA3 variant and portal/periportal histological pattern in patients with biopsy-proven non-alcoholic fatty liver disease: a possible role for oxidative stress 101
Long-term prediction of adherence to continuous positive air pressure therapy for the treatment of moderate/severe obstructive sleep apnea syndrome 99
Similar reduction of cholesterol-adjusted Vitamin E serum levels in simple steatosis and non-alcoholic steatohepatitis 95
Severity of OSAS, CPAP and cardiovascular events: a follow-up study 95
Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study 93
Relation of Nonalcoholic Fatty Liver Disease and Framingham Risk Score to Flow-Mediated Dilation in Patients With Cardiometabolic Risk Factors 92
Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically- versus genetically-driven excess fat hepatic storage 92
Overexpression of the vitronectin v10 subunit in patients with nonalcoholic steatohepatitis: Implications for noninvasive diagnosis of NASH 92
Oxidative stress: new insights on the association of nonalcoholic fatty liver disease and atherosclerosis 90
Progressive reduction of blood lysosomal acid lipase activity according to stage of adult chronic liver disease and altered enzymatic cellular distribution in cirrhosis 88
Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study 88
Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis 83
Reduced lysosomal acid lipase activity in blood and platelets is associated with nonalcoholic fatty liver disease 83
Obesity and Hypercholesterolemia are Associated with NOX2 Generated Oxidative Stress and Arterial Dysfunction 81
P848 SERUM CYTOKERATIN-18 IS ASSOCIATED WITH OXIDATIVE STRESS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE 81
Twelve variants polygenic score for low-density lipoprotein cholesterol distribution in a large cohort of patients with clinically diagnosed familial hypercholesterolemia with or without causative mutations 80
Reduced lysosomal acid lipase activity in adult patients with non-alcoholic fatty liver disease 80
Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants 78
Post-Implantation Syndrome. The impact of different devices for endovascular abdominal aortic aneurysm repair and related etiopathogenetic implications 76
Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease 74
Statins and non-alcoholic fatty liver disease 72
Non-alcoholic fatty liver disease and cardiovascular disease: Epidemiological, clinical and pathophysiological evidences 72
Prevalence and Impact of Nonalcoholic Fatty Liver Disease in Atrial Fibrillation 71
Incidence of post-implantation syndrome with different endovascular aortic aneurysm repair modalities and devices and related etiopathogenetic implications 71
Remnant lipoprotein cholesterol and cardiovascular and cerebrovascular events in patients with non-alcoholic fatty liver disease 70
Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease? 70
The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease 69
Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose 67
Current Ways of Treating Dyslipidemias to Prevent Atherosclerosis 66
The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease 66
Increased liver localization of lipopolysaccharides in human and experimental NAFLD 66
Moderate weight loss decreases oxidative stress and increases antioxidant status in patients with metabolic syndrome 65
Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment 64
Added fructose in non-alcoholic fatty liver disease and in metabolic sindrome. a narrative review 64
Sex-related differences in the association between metabolic syndrome and gallstone disease 64
Poor adherence to mediterranean diet and serum lipopolysaccharide are associated with oxidative stress in patients with non-alcoholic fatty liver disease 63
Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative Stress in Patients with Nonalcoholic Fatty Liver 61
HDL-mediated cholesterol efflux and plasma loading capacities are altered in subjects with metabolically-but not genetically driven non-alcoholic fatty liver disease (NAFLD) 60
New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress 59
Correction to: Reduced lysosomal acid lipase activity in blood and platelets Is associated with nonalcoholic fatty liver disease 59
Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease 58
The post-implantation syndrome(PIS). The impact of different devices for endovascular abdominal aortic aneurysm repair (EVAR) and related etiopathogenetic implications 56
Assessment of hepatic fibrosis in MAFLD..a new player in the evaluation of residual cardiovascular risk 56
Obstructive Sleep Apnea and the Metabolic Syndrome: Pathophysiological and Clinical Evidence 55
Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis 55
Modern approach to the clinical management of non-alcoholic fatty liver disease 53
P825 NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH REDUCED SERUM CHOLESTEROL-ADJUSTED VITAMIN E LEVELS 52
Predictors of weight loss in patients with obesity treated with a Very Low-Calorie Ketogenic Diet 51
High cardiovascular risk in non-alcoholic fatty liver disease: a possible role for increased oxidative stress. 51
Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease? 51
Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. a prospective multicenter cohort study 48
Cholesterol remnants, triglyceride-rich lipoproteins and cardiovascular risk 48
The challenge of cardiovascular prevention in NAFLD 46
Diet and metabolic syndrome. A narrative review 45
Statin use and mortality in atrial fibrillation. A systematic review and meta-analysis of 100,287 patients 45
Ridotta attività della lipasi acida lisosomiale: un possibile ruolo patogenetico nella nafld? 43
NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease 42
Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways 42
The intricacies of the Mediterranean diet in NAFLD. Response to Duret et al 40
Endotelial dysfunction and increased oxidative stress in patients with obstructive sleep dyspnea. Effect of CPAP therapy. 39
Extra virgin olive oil reduces gut permeability and metabolic endotoxemia in diabetic patients 38
The sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce platelet activation and thrombus formation by lowering NOX2-related oxidative stress: a pilot study 36
Sindrome delle apnee ostruttive del sonno e rischio cardiovascolare 34
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis 34
Nonalcoholic fatty liver disease and the kidney: a review 33
PNPLA3 I148M gene variant is not associated with metabolic syndrome and cardiometabolic risk in non-alcoholic fatty liver disease 32
Heterogeneity of non-alcoholic fatty liver disease (NAFLD): implication for cardiovascular risk stratification 31
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 31
High compliance to mediterranean diet associates with lower platelet activation and liver collagen deposition in patients with nonalcoholic fatty liver disease 29
null 27
Is the mediterranean diet the best approach to NAFLD treatment today 26
Metabolic syndrome but not fatty liver-associated genetic variants correlates with glomerular renal function decline in patients with non-alcoholic fatty liver disease 24
Open issues in the transition from nafld to mafld. the experience of the plinio study 23
Prevention and management of type ii diabetes chronic complications. the role of polyphenols (mini-review) 23
PAD4-Induced NETosis Via Cathepsin G-Mediated Platelet-Neutrophil Interaction in ChAdOx1 Vaccine-Induced Thrombosis-Brief Report 22
Commentary on "effect of green-mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial" 22
Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease 19
null 17
Oxidative stress mediated platelet activation in patients with congenital analbuminemia. Effect of albumin infusion 13
Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia. insights from the Italian LIPIGEN registry 12
Risk of adverse events in anticoagulated patients with atrial fibrillation and non-alcoholic fatty liver disease 11
Lipoprotein(a) genotype influences the clinical diagnosis of familial hypercholesterolemia 11
Challenges in improving adherence to diet and drug treatment in hypercholesterolemia patients 8
Influence of uric acid on vascular and cognitive functions: evidence for an ambivalent relationship 7
Totale 5.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.992
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.992
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020797 0 0 0 0 0 174 208 121 118 71 71 34
2020/2021704 50 29 20 61 15 73 10 20 63 220 115 28
2021/2022908 22 30 78 49 104 56 17 64 61 67 200 160
2022/2023957 168 201 52 62 72 84 21 119 57 21 63 37
2023/2024737 50 69 37 49 73 141 38 35 19 76 72 78
2024/2025538 36 84 100 120 104 94 0 0 0 0 0 0
Totale 5.614